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17-AAGSmall ubiquitin-related modiﬁers 1, 2 and 3 (SUMO-1, -2, -3), members of the ubiquitin-like protein family,
can be conjugated to various cellular proteins. Conjugates of SUMO-2 and SUMO-3 (SUMO-2/3) accumulate
in cells exposed to various stress stimuli or to MG132 treatment. Although the proteins modiﬁed by SUMO-2/
3 during heat shock or under MG132 treatment have been identiﬁed, the signiﬁcance of this modiﬁcation re-
mains unclear. Our data show that the inhibition of translation by puromycin or cycloheximide blocks both
the heat shock and MG132 induced accumulation of SUMO-2/3 conjugates in HEK 293T and U2OS cells. How-
ever, the heat shock induced accumulation of SUMO-2/3 conjugates was restored by proteasome inhibition,
which suggests that the inhibition of translation did not abolish SUMOylation itself. Furthermore, we show
that some of the proteins truncated due to the treatment by low concentration of puromycin are SUMOylated
in HEK 293T cells. We suggest that the SUMO-2/3 conjugates accumulating under the heat shock or MG132
treatment result largely from new protein synthesis and that portion of them is incorrectly folded.
© 2012 Elsevier B.V. All rights reserved.1. Introduction
Small ubiquitin-related modiﬁer (SUMO) is covalently attached to
protein targets by similar mechanism as ubiquitin and other mem-
bers of ubiquitin-like proteins group I. Yeast SUMO is encoded by a
single gene (smt3), while vertebrates have three independently
encoded SUMO isoforms. Human SUMO-1 exhibits approximately
51% sequence identity to human SUMO-2 and SUMO-3 isoforms. Pro-
cessed SUMO-2 exhibits approximately 97% sequence identity to pro-
cessed SUMO-3 (both together designated further as SUMO-2/3).
However, common enzymatic components are involved in conjuga-
tion of all three SUMO isoforms [1,2]. SUMO molecules are activated
by a nuclear [3,4] heterodimeric complex Aos1/Uba2 in an ATP-
dependent manner and then transferred to the Cys93 located in an ac-
tive site of Ubc9 (reviewed in [5]), which is the only known SUMO
conjugating enzyme. Ubc9 alone recognizes protein targets via short
amino acid motif with consensus sequence ΨKxE/D (Ψ — amino
acid with hydrophobic bulky side chain, x — any amino acid) and cat-
alyzes transfer of SUMO molecules to the internal lysine residue of
target proteins. Some proteins are modiﬁed in non-consensus sites
[6–9], but the mechanism of their recognition is still not well under-
stood. Although Ubc9 alone is able to SUMOylate most cellularucation Research Project grant
speciﬁc university research
rights reserved.protein targets, E3 SUMO ligases, such as RanBP2 [10,11], Pc2
[12,13], Topors [14] and PIAS [15,16], are necessary for higher
SUMOylation efﬁciency and selectivity. SUMO attached to a protein
target can induce its conformational changes, sterically inhibit its
DNA binding activity, modulate protein–protein interaction or in-
crease stability of the target by blocking lysine residue from ubiquity-
lation [17]. The SUMO attachment is a reversible modiﬁcation, the
isopeptide bond between SUMO and targets can be cleaved by
SUMO proteases (Ulp1 and Ulp2 in yeast, SENP1, 2, 3, 5, 6 and 7 in
vertebrates, reviewed in [18]).
Proteomic studies showed that some targets are selectively modi-
ﬁed by SUMO-1 or SUMO-2/3 isoforms [19] and it was further shown
that individual SUMO isoforms have different dynamic properties in
vivo [20]. However, disruption of both sumo-1 alleles in mouse did
not lead to observable developmental defects, which implies that
SUMO-2/3 can substitute function of SUMO-1 [21]. SUMO-2/3 can
form polymeric chains through lysine residue Lys11 located in the
SUMOylation motif of their ﬂexible N-termini [22,23]. The formation
of SUMO-1 chains via unknown non-consensus sites was also ob-
served both in vitro and in vivo [14,10], but it is unclear at this point
whether they are of any biological relevance. It was further reported
that SUMO-2/3 conjugates accumulated under different stress condi-
tions [24] and that part of these conjugates represented SUMO-2/3
chains [25]. Moreover, ubiquitin associated SUMO-2/3 conjugates
accumulated under proteasomal inhibition [26] and similar results
were observed with Smt3 in yeast [27]. SUMO-targeted ubiquitin
ligases RNF4 and Slx5/Slx8 were identiﬁed in vertebrates and yeast,
respectively, as the main linking factor between SUMOylation and
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and ubiquitylate SUMO-2 chains in vitro and that siRNA-based lower-
ing/depletion of RNF4 level leads to increased stability of SUMO-1 and
SUMO-2 conjugates [29]. Disruption of genes for RNF4 orthologues in
yeast also resulted in accumulation of Smt3 conjugates [28,30].
Although accumulation of SUMO-2/3 conjugates was described
under different stress conditions and the set of SUMO-2/3 targets
under heat shock or MG132 treatment has been determined [25,26],
the mechanism of target selection as well as the signiﬁcance of this
SUMO-2/3 conjugate accumulation remain to be determined. For
this reason, we were interested whether accumulation of SUMO-2/3
conjugates under heat shock or MG132 treatment was somehow
linked with the stress response on the transcription and translation
level. However, our data indicated that SUMO-2/3 conjugate accumu-
lation was rather linked with the global de novo protein synthesis
under these conditions. Here we show that SUMO-2/3 conjugates ac-
cumulating both under heat shock and MG132 treatment come main-
ly from new protein synthesis.
2. Materials and methods
2.1. Plasmid constructs
Plasmids encoding cMyc-SUMO-1 (pCMV-cMyc-SUMO1), HA-
SUMO-3 (pCMV-HA-SUMO3) and non-conjugable HA-SUMO-3 ΔG
(pCMV-HA-SUMO3 ΔG) were prepared as follows: SUMO-1 and
SUMO-3 coding sequences were isolated by RT-PCR from total RNA
of HeLa cells using primers S1+ (cgGAATTCtgtctgaccaggaggcaa-
aaccttc) and S1− (ttttCTCGAGttaaccccccgtttgttcctgataaact) for
SUMO1 and S3+ (cgGAATTCtgtccgaggagaagcccaaggaggg) and S3−
(ttttCTCGAGttaacctcccgtctgctgctggaacacgt) for SUMO3. To construct
pCMV-cMyc-SUMO1 and pCMV-HA-SUMO3 plasmids, the SUMO-1
and SUMO-3 coding sequences were inserted into the EcoRI and
XhoI sites of pCMV-cMyc and pCMV-HA plasmids (Clontech), respec-
tively. Plasmid pCMV-HA-SUMO3ΔG encodes SUMO-3 with deletion
of Gly 92. This SUMO-3ΔG sequence was obtained from pCMV-HA-
SUMO3 plasmid by PCR, using S3+ and S3ΔG− (cgcGGATCCttatc-
ccgtctgctgctggaacacgtcg) primers and then inserted into EcoRI and
BamHI sites of pCMV-HA plasmid. Plasmid pCMV-HA-SUMO3(ΔN)
encodes SUMO-3 with deletion of the ﬁrst 10 N-terminal amino acid
residues and with Lys11 to Ala11 substitution. This SUMO-3ΔN se-
quence was obtained from pCMV-HA-SUMO3 plasmid by PCR, using
S3 ΔN+ (CGGAATTCaaGCAacagagaatgaccacatcaacctgaagg) and S3−
primers and then inserted into EcoRI and XhoI sites of pCMV-HA plas-
mid. All obtained DNA constructs were veriﬁed by sequencing.
2.2. Cell cultures and transient transfection
HEK 293T, HeLa and U2OS cells were cultivated in Dulbecco's
modiﬁed Eagle's medium (DMEM; Sigma-Aldrich) supplemented
with 10% fetal bovine serum (FBS) and vitamins (both from Invitro-
gen) and penicillin/streptomycin/amphotericin B solution (Sigma-
Aldrich). Four hours prior to transfection, cells were plated on
35 mm tissue culture dish to 50% density and transient transfection
was carried out using polyethyleneimine (PEI; Polysciences) as fol-
lows: 4 μg of plasmid DNA and 12 μl of PEI solution (1 μg/μl PEI in
ddH2O) were mixed separately with 100 μl FBS-free DMEM. After
15 min, solutions were mixed together and transferred dropwise to
the culture dish. Expression of transfected genes was analyzed 12 h
post-transfection by Western blot.
2.3. Western blot analysis
Cells on 35 mm tissue culture dish were directly lysed in 150 μl of
2× concentrated Laemmli buffer (100 mM Tris, pH 6.8, 8% SDS, 24%
glycerol, 0.02% Coomassie blue G-250, 200 mM dithiothreitol), boiledfor 5 min and sonicated to lower sample viscosity. Cell lysates were
separated by 9.6% Tris-tricine SDS-PAGE and electroblotted to a nitro-
cellulose membrane. Membrane was incubated in blocking solution
(5% fat-free milk, 0.1% Tween-20 in PBS) for 1 h. Endogenous
SUMO-2/3 was detected using polyclonal anti-SUMO-2 antibody
(Invitrogen) in dilution 1:750. Myc and HA fused proteins were
detected using relevant epitope tag speciﬁc, mouse monoclonal anti-
bodies (both purchased form Sigma-Aldrich), in dilution 1:5000.
Protein level normalization was carried out by rabbit polyclonal
anti-GAPDH antibody (Sigma-Aldrich), used in dilution 1:10,000. Sec-
ondary anti-mouse and anti-rabbit IgG speciﬁc HRP-conjugated anti-
bodies (Promega) were used in dilution 1:4000. Immunoblots were
visualized by Super Signal West Femto chemiluminescent substrate
(Pierce) according to the manufacturer's instructions. The quantiﬁca-
tion of immunoblots was carried out using TotalLab TL100 software
(Nonlinear USA Inc., NC, USA).
2.4. Inhibition of translation, proteasome inhibition, heat shock and
inhibition of Hsp 90
To inhibit translation, cells were treated with 30 μg/ml cyclohexi-
mide or 100 μg/ml puromycin for 20 min. Proteasomal activity was
inhibited by 20 μM MG132. All inhibitors were purchased from
Sigma-Aldrich. Heat shock was performed by incubation of the cells
for 45 min in a CO2 incubator preheated to 42 °C. In case of combina-
tion of inhibitor treatment and heat shock, cells were ﬁrst subjected
to either translational or proteasomal inhibitor for 20 min. Subse-
quently and without removal of the particular inhibitor, each cell
sample was then subjected to an additional 45 min of heat shock.
In case of combination of translational and proteasomal inhibitor
treatment, cells were ﬁrst subjected to translational inhibition for
20 min. Subsequently and without removal of the translational inhib-
itor, each cell sample was then exposed to proteasomal inhibitor
MG132 for 80 min. To inhibit Hsp 90 activity, cells were treated by
20 μM 17-AAG (Selleck) for 40 min.
2.5. Induction and monitoring of synthesis of truncated proteins
To test the ability of different concentrations of puromycin to in-
duce truncated protein synthesis, HEK 293T cells on 35 mm Petri
dish were washed twice by PBS and cultivated in FBS-free DMEM
without methionine/cysteine (Sigma-Aldrich) in presence of puromy-
cin in range from 0.5 to 100 μg/ml. After 20 min, [35S]-methionine/
cysteine (TRAN35S-LABEL™; MP Biomedicals) was added to ﬁnal spe-
ciﬁc activity 50 μCi/ml. After 20 min incubation, the labeling medium
was discarded and cells were directly lysed in 500 μl of 2× concentrat-
ed Laemmli buffer. Total lysates were boiled for 10 min and analyzed
by Tris-tricine SDS-PAGE. Radiolabeled translation products were
visualized by phosphorimaging. To induce synthesis of truncated pro-
teins in our experiments, the cells were treated with 10 μg/ml puro-
mycin for 20 min.
2.6. SUMO deconjugation
For SUMO deconjugation from intracellular targets, HEK 293T cells
were pelleted and the cell pellet was resuspended in 100 μl of native
lysis buffer (50 mM TrisHCl, 150 mM NaCl, 0,4% NP-40, 1 mM DTT,
1 mM EDTA, 20 μM MG132, 20 μg/ml Leupeptin, 1 mM PMSF, pH 8),
alternatively containing S. cerevisiae Ulp1 (Invitrogen). The lysates
were incubated for 2 h at room temperature.
2.7. Determination of SUMOylation of newly synthesized proteins
HEK 293T cells were transfected by plasmid pCMV-HA-SUMO-3 at
50% density on 60 mm Petri dish. After 12 h cells were washed two-
times by DMEM without methionine/cysteine and radiolabeled by
Fig. 1. Effect of puromycin or cycloheximide treatment on protein synthesis. HEK 293T
cells were treated with different concentrations of puromycin or cycloheximide for
20 min and then subjected to the [35S]-methionine radiolabeling of translated products
for 20 min. Total cell lysates were analyzed by SDS-PAGE and radiolabeled translation
products were visualized by phosphorimaging (upper panel). Coomassie blue staining
was used as a control of total protein levels (lower panel).
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medicals) for 60 or 120 min at conditions described in individual ex-
periments. Cells were released by 1 ml of the original cultivation
medium and the resulting cell suspension was equally divided into
two parts (designated here as portion A and B). Cells were pelleted
at 1000×g for 1 min and the cell pellet was treated as follows. Portion
A (deconjugation of HA-SUMO-3): HA-SUMO-3 was deconjugated as
described in 2.6, SDS was then added to ﬁnal concentration of 2%. Ly-
sates were boiled for 10 min, intensively sonicated and diluted by
900 μl of dilution buffer (10 mM Tris.HCl, 150 mM NaCl, 1% Triton
X-100, 2 mM EDTA, pH 8). Portion B (isolation of HA-SUMO-3 conju-
gates): The cell pellet was resuspended in 100 μl of denaturation
lysis buffer (10 mM Tris.HCl, 150 mM NaCl, pH8, 2% SDS, 10 mM
NEM, 5×conc. inhibitor cocktail (Complete, Roche), 1 mM PMSF),
boiled for 10 min, intensively sonicated and diluted by 900 μl of dilu-
tion buffer. Following operations were identical for both A and B ly-
sates. Diluted lysates were incubated at 4 °C for 30 min on a rotator,
centrifuged (20,000×g, 30 min, 20 °C) and supernatant was har-
vested. 40 μl of 50% suspension of anti-HA agarose (Sigma) was
added to the supernatant and incubated at 4 °C for 3 h on a rotator.
The resin was washed four-times by washing buffer (10 mM Tris.HCl,
1 M NaCl, 1% NP-40, 1 mM EDTA, pH 8). The resin was then resus-
pended in 5 ml of liquid scintillation cocktail and radioactivity of sam-
ples was measured by liquid scintillation detector (Beckman).
3. Results
3.1. Effect of translational inhibitors on accumulation of SUMO-2/3
conjugates under heat shock and under proteasomal inhibition
It has been previously shown that in contrast to SUMO-1, the level
of SUMO-2/3 conjugates is increased in response to various types of
stress including heat shock [24] and, furthermore, the set of SUMO-
2/3 targets under heat shock has been determined [25]. We followed
these studies and investigated effect of translational inhibitors, cyclo-
heximide and puromycin, on accumulation of SUMO-2/3 conjugates
under the heat shock. Translation inhibition should abolish the tran-
scriptional heat shock response by inactivation of de novo protein
synthesis. To avoid possible detrimental side-effects of translational
inhibitors, we ﬁrst tested the impact of different concentrations of
the inhibitors on protein synthesis over a short time treatment. HEK
293T cells were treated for 20 min with puromycin at concentration
range 0.5–100 μg/ml or with cycloheximide at concentration range
0.1–30 μg/ml with consequent 20 min [35S]-methionine radiolabel-
ing. The molecular mass and amounts of the synthesized proteins
were determined by SDS-PAGE followed by autoradiography
(Fig. 1). Puromycin at concentration 100 μg/ml and cycloheximide
at concentration 30 μg/ml totally inhibited protein synthesis. Howev-
er, in contrast to cycloheximide, puromycin at lower concentrations
(5, 10 and 20 μg/ml) caused visible shortening of newly synthesized
proteins (Fig. 1).
To totally block protein synthesis, HEK 293T, U2OS and HeLa
cells were treated with cycloheximide (30 μg/ml) or puromycin
(100 μg/ml) and the cells were then subjected to the heat shock.
Total cell lysates were analyzed by Western blot for the content of
SUMO-2/3 conjugates. U2OS and HEK 293T cells untreated by transla-
tional inhibitors accumulated SUMO-2/3 conjugates under heat
shock, which correlates with the lower level of free (unconjugated)
SUMO-2/3 when compared to the control cells cultivated at 37 °C
(Fig. 2A and C, compare lanes 1 and 2). However, pretreatment of
U2OS and HEK 293T cells by puromycin and cycloheximide was
linked with block of SUMO-2/3 conjugates accumulation under heat
shock. This observation was also in correlation with the level of free
SUMO-2/3, which was comparable to the cells, both untreated and
treated by translational inhibitors, cultivated at 37 °C (Fig. 2A and C,
compare lanes 3 and 4, 5 and 6, free SUMO-2/3). In HeLa cells, heatshock induced accumulation of SUMO-2/3 conjugates under our
experimental conditions was not observed (Fig. 2B, compare lines 1
and 2), therefore the effect of translation inhibitors could not be
determined.
Since accumulation of SUMO-2/3 conjugates has been reported
also under proteasomal inhibition, both in yeast and mammalian
cells [26,27], we investigated effect of the translational inhibitors on
accumulation of SUMO-2/3 conjugates under MG132 treatment.
HEK 293T, U2OS and HeLa cells were treated with translational inhib-
itor and subsequently with proteasomal inhibitor MG132. When cells
were treated by MG132 alone, all tested cell lines showed accumula-
tion of SUMO-2/3 conjugates (Fig. 2A–C, compare lanes 7 and 8). In
case of pretreatment by translational inhibitors, the MG132-induced
accumulation of SUMO-2/3 conjugates was blocked in all three tested
cell lines (Fig. 2A–C, compare lanes 9 or 10 with lane 8).
The intracellular level of SUMO-2/3 conjugates is a result of equi-
librium between their formation on one side and deconjugation and/
or degradation on the other side. For this reason, we examined effect
of cycloheximide treatment on SUMO-2/3 conjugates accumulation
during heat shock in combination with proteasomal inhibition in
HEK 293T cells (Fig. 3). As already shown above, inhibition of protein
synthesis blocked both the heat shock and MG132 induced SUMO-2/3
conjugates accumulation (Fig. 3, compare lane 3 with 4 and lane 5
with 7, respectively; Fig. 4A, compare conditions 1 with 2 and 3,
and next, 7 with 8 and 9, respectively). However, accumulation of
SUMO-2/3 conjugates under heat shock and translational inhibition
was restored by MG132 treatment to the level comparable with con-
trol untreated cells under the heat shock (Fig. 3, compare lane 4 with
8 and next lane 2 with 8, Fig. 4A, compare conditions 2 with 4 and 3
with 5). That suggests that inhibition of translation did not abolish
SUMOylation itself. Furthermore, the inhibition of translation did
not lead to the decrease of the intracellular SUMO level (Supplemen-
tary Fig. 1) but rather it somehow inﬂuenced the level of the SUMOy-
lation targets.3.2. Newly synthesized proteins as targets of SUMOylation
In the above-described experiments, we used puromycin in con-
centration completely abolishing translation (100 μg/ml). Since
the treatment with low concentration of puromycin (5, 10 and
Fig. 2. Effect of translational inhibitors on accumulation of SUMO-2/3 conjugates. Total cell lysates were analyzed by Western blot followed by immunodetection using anti-SUMO-
2/3 antibody. A. Left panel: U2OS cells were treated with translation inhibitors, 30 μg/ml cycloheximide or 100 μg/ml puromycin, for 20 min with consequent 45 min heat shock
(42 °C). Inhibition of translation prevented the heat shock induced accumulation of SUMO-2/3 conjugates (lanes 4 and 6). Right panel: U2OS cells were treated with translation
inhibitors, 30 μg/ml cycloheximide or 100 μg/ml puromycin, for 20 min with consequent 80 min MG132 treatment. Inhibition of translation prevented the MG132 induced accu-
mulation of SUMO-2/3 conjugates (lanes 9 and 10). B. Same as in A., but HeLa cells were used. In case of heat shock, HeLa cells did not accumulate SUMO-2/3 conjugates under
our experimental conditions, so the effect of translation inhibitors could not be determined. C. Same as in A., but HEK 293T cells were used.
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(peptides) (Fig. 1), we decided to investigate the effect of synthesis
of truncated proteins on SUMO-2/3 conjugates accumulation. To in-
duce formation of defective truncated proteins in our experiments
we chose puromycin concentration of 10 μg/ml (Fig. 1).
HEK 293T cells were treated with puromycin (10 μg/ml or
100 μg/ml) for 20 min and subsequently the proteasome inhibitor
MG132 was added for next 20 or 80 min. The cell lysates were ana-
lyzed by Western blot using antibody against SUMO-2/3 (Fig. 4B).Puromycin at concentration 100 μg/ml prevented the MG132-
induced accumulation of SUMO-2/3 conjugates (Fig. 4B, compare
lanes 4 and 12, Fig. 4A, compare conditions 7 and 8). On the other
hand, treatment with low concentration of puromycin (10 μg/ml)
in combination with MG132 resulted in accumulation of not only
high molecular mass SUMOylated species, but of SUMOylated
species of lower molecular mass (approx. from 35 kDa) as well
(Fig. 4B, lane 8, Fig. 4A, condition 10). Since the puromycin treat-
ment at concentration 10 μg/ml led to production of defective
Fig. 3. Effect of cycloheximide and MG132 on accumulation of SUMO-2/3 conjugates
under heat shock. HEK 293T cells were pre-treated with 30 μg/ml cycloheximide for
20 min, then 20 μM MG132 was added for another 20 min and consequently the cells
were subjected to heat shock (42 °C) for 45 min. MG132 alone induced SUMO-2/3 con-
jugates accumulation both at 37 °C and at 42 °C (lanes 7 and 8). At 37 °C, the MG132
induced SUMO-2/3 conjugates were considerably reduced when translation was ﬁrst
inhibited by cycloheximide (lane 9). However, at 42 °C and under MG132 treatment
the accumulation of SUMO-2/3 conjugates was not prevented by translation inhibition
(lane 10).
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tween 6 and 45 kDa (Fig. 1, puromycin 10 μg/ml), we suppose that
the low molecular mass SUMOylated species represent some of
these truncated proteins modiﬁed by SUMO-2/3. Furthermore, HA-
SUMO-3 and Myc-SUMO-1 were co-expressed and the effect of pu-
romycin on their conjugation was tested (Fig. 5A). The accumulation
of HA-SUMO-3 conjugates under proteasomal inhibition after the
puromycin (10 μg/ml) treatment showed similar pattern as in case
of endogenous SUMO-2/3 (Fig. 5A, lower panel). On the other
hand, no visible change in conjugation of Myc-SUMO-1 was ob-
served in any case of puromycin or MG132 treatment, or theirFig. 4. SUMOylation of newly synthesized truncated proteins. A. Quantiﬁcation of SUMO-2/3
of content of SUMO-2/3 conjugates in cells at appropriate conditions to SUMO-2/3 conjugate
in Materials and methods. The immunoblots were analyzed by TotalLab TL100 software. P
30 μg/ml. Error bars represent conﬁdence for α=0.05 and four independent experiments
MG132 treatment for next 20 or 80 min. Total cell lysates were analyzed by Western blot
(10 μg/ml) in combination with MG132, cells accumulated not only high molecular mass
35 kDa, see lane 8). These low molecular mass SUMOylated species were also slightly vis
when translation was ﬁrst totally inhibited by 100 μg/ml puromycin with consequent expocombination (Fig. 5A, upper panel). Formation of the high molecular
mass SUMO-2/3 or HA-SUMO-3 conjugates under the puromycin
treatment (10 μg/ml) could originate from polySUMOylation. This
possibility is supported by the decrease of molecular mass of the
HA-SUMO-3ΔN mutant conjugates, lacking among others the
Lys11 residue responsible for SUMO-2/3 chain formation (Fig. 5B).
Under the puromycin treatment (10 μg/ml), formation of ubiqui-
tylated SUMO-2/3 or HA-SUMO-3 truncated products cannot be ex-
cluded. However, in the case of over-expression of non-conjugable
HA-SUMO-3ΔG mutant, puromycin treatment in combination with
MG132 did not result in formation of any other species recognized
by anti-HA antibody than free SUMO-3ΔG (Supplementary Fig. 2).
This supports our assumption that the low molecular mass species
represent truncated proteins modiﬁed by either SUMO-2/3 or HA-
SUMO-3.
The blocked accumulation of SUMO-2/3 conjugates under MG132
or 42 °C treatment when translation is inhibited, and on the other
hand, the accumulation of SUMO-2/3 conjugates when truncated pro-
tein synthesis is induced, suggests that some of the newly synthesized
proteins may be targets for SUMOylation. This possibility was con-
ﬁrmed by immunoprecipitation of HA-SUMO-3 conjugates from radi-
olabeled HEK 293T cells. To avoid false positive results caused by
newly synthesized and therefore radiolabeled, HA-SUMO-3, each
sample was equally divided and HA-SUMO-3 in one aliquot was
deconjugated in vitro by endogenous SUMO proteases in combination
with addedUlp1 (Supplementary Fig. 3) prior to immunoprecipitation
of HA-SUMO-3 under denaturing conditions. Ratio of radioactivity
(cpm values) of conjugated/deconjugated HA-SUMO-3 imunoprecipi-
tates from unstressed HEK 293T cells was near to 1:1, indicating that
HA-SUMO-3 was not conjugated to newly synthesized proteins
(Fig. 6). On the other hand, the cpm ratio was in interval from 1.4 to
1.6 for cells cultivated in presence of MG132 (120 min) or MG132
and 10 μg/ml puromycin (120 min) or under 42 °C (60 min). Thisconjugates content under different conditions in HEK 293T cells. y axis represents ratio
s in control untreated cells cultivated at 37 °C. Treatments were carried out as described
URO-100 or PURO-10 — puromycin 100 μg/ml or 10 μg/ml, CHX-30 — cycloheximide
(n=4). B. HEK 293T cells were treated with puromycin for 20 min with consequent
using anti-SUMO-2/3 antibody. After the addition of low concentration of puromycin
SUMOylated species but also SUMOylated species of lower molecular mass (cca from
ible after prolonged exposure of control cells to MG132 (lane 4), but not in the case
sition to the proteasome inhibition (lane 12).
Fig. 5. SUMOylation of truncated proteins preferentially by HA-SUMO-3. Total cell ly-
sates were analyzed by Western blot followed by immunodetection using anti-HA or
anti-Myc antibody. A. HEK 293T cells were co-transfected with pCMV-HA-SUMO-3
and pCMV-Myc-SUMO-1 and then treated as described in legend of Fig. 3B. Both low
and high molecular mass conjugates accumulated after induction of defective short
protein synthesis and proteasome inhibition in case of HA-SUMO-3 (lower panel, lane
8), but not in case of Myc-SUMO-1 (upper panel, lane 8). B. HEK 293T cells were trans-
fected with pCMV-HA-SUMO-3 or pCMV-HA-SUMO-3ΔN, encoding HA-SUMO-3 mu-
tant defective in Lys11 chain formation. Transfected cells were treated with 10 μg/ml
puromycin for 20 min with consequent MG132 treatment for 80 min and total cell ly-
sates were analyzed by 10% Tris-tricine (left panel) or 6% Tris-glycine (right panel) SDS-
PAGE followed by Western blot analysis. In both cases, induced accumulation of SUMO
conjugates was observed under the treatment, however, molecular mass of SUMO con-
jugates was decreased in case of HA-SUMO-3ΔN mutant.
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proteins were covalently associated with HA-SUMO-3 under these
conditions.The fact that the truncated proteins synthesized after puromycin
(10 μg/ml) treatment are highly unstable in vivo and their stability
depends on proteasomal activity (Supplementary Fig. 4) suggests
that their folding could be compromised due to premature termina-
tion of translation. In this context we examined effect of 17-AAG,
the inhibitor of Hsp 90 activity [31,32], on SUMOylation (Fig. 7).
Treatment of HEK293T cells by combination of 17-AAG and MG132
for 40 min resulted in accumulation of SUMO-2/3 conjugates, which
was not observed when only MG132 was used or when translation
was ﬁrst inhibited by cycloheximide.
4. Discussion
In this study, we showed that both the heat shock and MG132 in-
duced accumulation of SUMO-2/3 conjugates can be blocked by inhi-
bition of translation in HEK 293T and U2OS cells. Although the study
is based mainly on the use of chemical inhibitors we ﬁrmly believe
that our results are signiﬁcant. To eliminate the possibility of side ef-
fects of the translation inhibitors we used two mechanistically differ-
ent translational inhibitors, puromycin and cycloheximide. In case of
puromycin, the puromycyl peptides are released from ribosome, ribo-
somal subunits dissociate from mRNA and they are ready for the new
initiation of translation [33]. Cycloheximide, on the other hand,
blocks ribosomal peptidyltransferase activity, which results in poly-
somes stabilization [34,35]. Moreover, in this study the inhibitors
were used for short time periods to avoid detrimental biological
side effects.
The accumulation of SUMO-2/3 conjugates under different stress
conditions may be caused by various events. For example, activity of
proteasomes or SUMO proteases could be decreased, activity of
SUMOylation machinery could be increased, new types of SUMO-2/
3 targets could be generated or combination of these events might
occur. Previously, it was shown that treatment with MG132 or other
types of proteasomal inhibitors increase the level SUMO-2/3 conju-
gates in vivo [26,27], which suggest that proteasomes could play
an important role in the SUMO-2/3 conjugates stability. Our data
showed that the MG132-induced accumulation of endogenous
SUMO-2/3 conjugates was blocked when translation was ﬁrst abol-
ished by treatment with cycloheximide or puromycin, in all three
tested cell lines — HeLa, U2OS and HEK 293T (Fig. 2 A–C, lines
7–10). It is necessary to note that accumulation of HA-SUMO-3 conju-
gates in HEK 293T under proteasomal inhibition was also abolished
by block of translation (Fig. 5A, lower panel, compare line 4 and
12). Since both these mechanistically different translational inhibitors
have similar negative impact on MG132-induced accumulation of en-
dogenous SUMO-2/3 conjugates, we suggest, that the SUMOylation is
directly linked with proteosynthetic activity of ribosomes, namely,
there is relation between accumulation of SUMO-2/3 conjugates and
production of newly synthesized proteins during MG132 treatment.
This idea is supported by the results of the experiment in which com-
bination of MG132 with 10 μg/ml puromycin was used. Puromycin at
this concentration did not block translation completely, but it caused
production of truncated proteins with mobility corresponding up to
~45 kDa (Fig. 1). Puromycin treatment at this concentration was ac-
companied by accumulation of endogenous SUMO-2/3 conjugates of
lower molecular mass (Fig. 4B, lane 8). Furthermore, when HA-
SUMO-3 and Myc-SUMO-1 were co-expressed, only low molecular
mass conjugates of HA-SUMO-3 did accumulate, but not those of
Myc-SUMO-1 (Fig. 5A, lane 8). We suggest that these low molecular
mass SUMO-2/3 or HA-SUMO-3 conjugates represent part of the
newly synthesized truncated proteins, namely puromycyl peptides,
modiﬁed by SUMO-2/3 or HA-SUMO-3 and that their stability de-
pends on proteolytic activity of proteasomes. It was previously
reported that puromycyl peptides are rapidly degraded in vivo
[36,37] and we suggest that a part of them is modiﬁed by SUMO-2/
3 before degradation. However, puromycin at concentration 10 μg/
Fig. 6. Conjugation of HA-SUMO-3 to newly synthesized proteins. HEK 293T cells over-
expressing HA-SUMO-3 were radiolabeled using [35S]-methionine for 120 or 60 min
at indicated conditions (1–37 °C; 2–37 °C, 10 μM MG132; 3–37 °C, 10 μM MG132,
10 μg/ml puromycin; 4–42 °C) and both conjugated and deconjugated HA-SUMO
under indicated conditions were immunoprecipitated in parallel as described in Sec-
tion 2.7. Data are presented as a ratio of cpm of conjugated to deconjugated HA-
SUMO-3 in the immunoprecipitate. Error bars represent conﬁdence for α=0.05 and
three independent experiments (n=3).
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lecular mass SUMO conjugates as well, especially when HA-SUMO-3
was over-expressed (Fig. 5A, lower panel, lane 8). These might repre-
sent truncated proteins with multiple (poly)SUMO-2/3 modiﬁcations
(Fig. 5B), additional ubiquitylation of which cannot be excluded
[22,23,25–27]. The low molecular mass SUMOylated species may be
also, but in a lower content, detected in the MG132 treated cells
(Fig. 4B, line 4), but not when translation was ﬁrst completely inhib-
ited by 100 μg/ml puromycin and when the proteasomes were conse-
quently inhibited (Fig. 4B, line 12). We suggest that these low
molecular mass SUMO conjugates result from naturally occurring ab-
errant translational products and that they accumulate under protea-
somal inhibition.
Cycloheximide and puromycin also blocked the accumulation
of heat-induced SUMO-2/3 conjugates in U2OS and HEK 293T cells
(Fig. 2A and C, lanes 1–6). However, since the accumulation of
SUMO-2/3 conjugates under heat shock and translation inhibition
was restored by MG132 treatment (Fig. 3, compare line 4 with 8),
we suggest that the inhibition of translation during the heat shock
do not abolish SUMOylation itself. Rather, it affected the level of
SUMOylation targets and most of the newly formed SUMO-2/3
conjugates under the heat shock, when translation is inhibited, areFig. 7. Effect of 17-AAG on accumulation of SUMO-2/3 conjugates. HEK 293T cells were pre-
without 20 μM 17-AAG for another 40 min at 37 °C. A. Immunochemical detection of SUMO
dence for α=0.05 and four independent experiments (n=4). After 40 min, MG132 alone
observed when MG132/17-AAG was used.degraded by proteasomes. From this perspective, it looks as though
the SUMO-2/3 conjugates accumulated during heat shock comprise
both the SUMO-2/3 modiﬁed newly synthesized proteins and the
SUMO-2/3 modiﬁed proteins synthesized before the heat shock. On
the other hand, especially newly synthesized proteins seem to be
SUMOylated under MG132 treatment (Fig. 3, compare lanes 3, 5 and
7). Covalent HA-SUMO-3 association with subset of newly translated
proteins (Fig. 6) documents that there is a direct connection between
HA-SUMO-3 conjugation and new protein synthesis under MG132 or
MG132/puromycin (10 μg/ml) treatment or under heat shock.
The dependence of SUMO-2/3 conjugates stability on proteasomal
activity both at 37 °C and 42 °C generates a question, which types of
proteins are selected as targets. Many SUMOylated proteins have
been already identiﬁed both under normal and stress conditions
[9,25]. However, biological signiﬁcance of the stress induced SUMOy-
lation is not yet clear. It is well known that natural transcriptional/
translational errors lead to production of unfolded or misfolded pro-
teins and that their load could be increased under different stress
stimuli. This can happen primarily due to the direct impact of stress
factors on protein folding and secondary due to the saturation of a
chaperone system. It is possible that just a part of these unfolded/mis-
folded proteins is SUMOylated under stress conditions. This is sup-
ported by the experiments with puromycin (10 μg/ml) treatment,
which resulted in formation of low molecular mass SUMO-2/3 conju-
gates, representing part of the newly synthesized truncated proteins
modiﬁed by SUMO-2/3, folding of which could be compromised due
to premature termination of their translation. Our assumption about
incorrect folding of a substantial subset of the truncated proteins is sup-
ported by their rapid degradation by proteasomes (Supplementary Fig.
4). Furthermore, we showed a correlation between inhibition of activity
of Hsp 90 by 17-AAG, the chaperone included in the last step of folding
machinery [38,39], and increased accumulation of SUMO-2/3 conjugates
(Fig. 7). The fact that inhibition of translation abolished the accumulation
of SUMO-2/3 conjugates under the 17-AAG/MG132 treatment suggests
that the fold of the newly synthesized proteins could be a critical param-
eter for SUMO-2/3 target selection. An example of the relationship be-
tween protein misfolding and SUMOylation has already been reported
for PML protein [40]. In this case, binding of As(III) ion to PML zinc ﬁnger
led to conformational change and aggregation of PML, which then efﬁ-
ciently interactedwithUbc9 andwas polySUMO-2ylated in vitro. Another
example is SUMOylation of a yeast transcription factorMot1,which is tar-
geted for Smt3mediated degradation due to a temperature sensitivemu-
tation or due to the incorporation of canavanine, an arginine analog [41].
SUMOylation of other proteins increased upon canavanine treatment astreated with 30 μg/ml cycloheximide for 20 min, then 20 μMMG132 was added with or
-2/3 conjugates. B. Quantiﬁcation of SUMO-2/3 conjugates. Error bars represent conﬁ-
did not induce SUMO-2/3 conjugates accumulation. However, their accumulation was
Fig. 8. Scheme illustrating suggested relation between translation and accumulation of SUMO-2/3 conjugates. Under normal conditions (1), the detected SUMO-2/3 conjugates rep-
resent mainly various modiﬁed nuclear factors (e.g. PML protein). If translation is blocked by cycloheximide (CHX) or puromycin 100 μg/ml (PURO-100) under MG132 treatment
(2), accumulation of SUMO-2/3 conjugates is not observed. When translation is not blocked during MG132 treatment (3), the SUMO-2/3 conjugates accumulate. When synthesis of
short aberrant proteins is induced by puromycin 10 μg/ml (4), the SUMO-2/3 conjugates do not accumulate, however, they are observed when proteasomal activity is blocked (5).
Part of these conjugates is of lower molecular mass compared to case (3). These data indicate that during MG132 treatment mainly unfolded/misfolded newly synthesized proteins
modiﬁed by SUMO-2/3 do accumulate. Under heat shock, the SUMO-2/3 conjugates accumulate (6), but not when translation is blocked (7). However, the accumulation of SUMO-
2/3 conjugates can be restored by proteasomal inhibition (8). Taken together, the SUMO-2/3 conjugates accumulated under heat shock comprise both the SUMO-2/3 modiﬁed
newly synthesized proteins and the SUMO-2/3 modiﬁed proteins synthesized before the heat shock.
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upon canavanine treatment [41].
These reported ﬁndings together with our data support our hy-
pothesis that a part of the newly synthesized unfolded/misfolded pro-
teins could be SUMOylated and that SUMOylation might represent a
quality control mark of protein folding. However, the “added value”
of SUMOylation is so far unclear, especially when ubiquitylation has
been shown to be directly linked with co-translational control of pro-
tein folding [42–45].
5. Conclusion
We showed that conjugates of endogenous SUMO-2/3 accumulating
under heat shock or MG132 treatment largely represent modiﬁed pro-
teins generated from new protein synthesis. Next, we propose that
these SUMOylated targets could be unfolded/misfolded proteins and
stability of these conjugates depends on proteasomal activity (Fig. 8).
Supplementary materials related to this article can be found on-
line at doi:10.1016/j.bbamcr.2012.01.010.
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